Loading...
01/11 03:35
Loading...
Access earnings results, analyst expectations, report, slides, earnings call, and transcript.
The earnings call reveals strong financial performance, with significant revenue and margin growth, reduced expenses, and improved net loss. The partnership with Zimmer Biomet and international expansion plans are promising. Despite management's cautious stance on 2026 guidance, the optimistic FY 2025 outlook and strategic partnerships suggest a strong positive sentiment. The Q&A session highlights potential growth areas and addresses concerns, further solidifying the positive outlook. Given the context and potential for expansion, a strong positive stock price movement is expected, likely exceeding 8%.
Product Revenue Increased 105% to $1.7 million in Q3 2025 compared to $0.8 million in Q3 2024. This growth highlights the strength of the current business and efforts to reduce costs.
Product Gross Margins Increased to 53.9% in Q3 2025 compared to 34.1% in Q3 2024. This improvement is attributed to cost reduction efforts.
Product Revenue (First 9 Months) Increased 100% to $6.4 million in the first 9 months of fiscal 2025 compared to $3.2 million in the same period of fiscal 2024.
Licensing Revenue Generated $3 million in the first 9 months of fiscal 2025 compared to no licensing revenue in the same period of fiscal 2024. This revenue came from the expanded exclusive distribution agreement with Zimmer Biomet.
Product Gross Profit Increased to $0.9 million (53.9% of revenue) in Q3 2025 compared to $0.3 million (34.1% of revenue) in Q3 2024. For the first 9 months of fiscal 2025, it increased to $3.6 million (56.8% of revenue) compared to $0.9 million (29.5% of revenue) in the same period of fiscal 2024.
Total Operating Expenses Decreased 9% to $2.8 million in Q3 2025 compared to $3.1 million in Q3 2024. For the first 9 months of fiscal 2025, total operating expenses decreased 5% to $9.5 million compared to $10.0 million in the same period of fiscal 2024.
Net Loss Improved to $1.5 million (loss of $0.03 per share) in Q3 2025 compared to $2.8 million (loss of $0.10 per share) in Q3 2024. For the first 9 months of fiscal 2025, net loss improved significantly to $2 million (loss of $0.05 per share) compared to $9 million (loss of $0.35 per share) in the same period of fiscal 2024.
Cash and Cash Equivalents Increased to $8 million as of June 30, 2025, compared to $1.5 million as of September 30, 2024.
Working Capital Increased to $8.7 million as of June 30, 2025, compared to $2.4 million as of September 30, 2024.
OneRF ablation system: Achieved successful patient outcomes, including the first patient reaching 1-year seizure freedom milestone. Planning to initiate a post-market registry to collect outcomes data.
Pain management technology: Submitted a 510(k) to the FDA for trigeminal neuralgia treatment. Exploring additional opportunities in pain management and therapeutic applications.
Spinal cord stimulation electrode: Launched a chronic animal study, with potential first-in-man implants in early 2026. Represents a $3 billion market opportunity.
Drug delivery system: Received first order from a biotech company to test the system for therapy delivery and brain activity recording.
International market expansion: Initiating ISO 13485 certification process to commercialize products internationally. No prior international sales, but potential for significant revenue.
Revenue growth: Product revenue increased 105% year-over-year to $1.7 million in Q3 2025. Fiscal year 2025 guidance projects $8-10 million in revenue, a 132%-190% increase over 2024.
Gross margin improvement: Product gross margins increased to 53.9% in Q3 2025 from 34.1% in Q3 2024. Fiscal year 2025 gross margin guidance raised to 50%-53%.
Cost management: Operating expenses decreased 9% in Q3 2025. Net loss improved to $1.5 million from $2.8 million year-over-year.
Partnerships and collaborations: Expanded exclusive distribution agreement with Zimmer Biomet, generating $3 million in licensing revenue in the first 9 months of 2025.
Intellectual property: Received a U.S. patent allowance for a novel manufacturing method and the first international patent for spinal cord stimulation electrode.
Leadership strengthening: Hired Dr. Parag Patil as Chief Medical Adviser and Emily Johns as General Counsel, contributing to cost savings and operational improvements.
Regulatory Approvals: The company is awaiting FDA clearance for its trigeminal neuralgia ablation technology. Delays or failure to obtain this clearance could impact commercialization and revenue generation.
International Market Expansion: The company has not yet sold or commercialized products internationally and is in the process of securing ISO 13485 certification. Failure to achieve this certification could limit revenue opportunities in international markets.
Product Development Risks: The company is pursuing multiple new applications for its technology, including lower back pain treatment and spinal cord stimulation. Delays or failures in product development, clinical trials, or regulatory approvals could hinder market entry and revenue growth.
Strategic Partnerships: The company is in discussions with strategic partners for various applications. Failure to secure these partnerships could limit commercialization and market penetration.
Financial Sustainability: While the company is currently debt-free and funded through fiscal 2026, achieving cash flow breakeven is contingent on hitting key milestones. Failure to meet these milestones could strain financial resources.
Intellectual Property Risks: The company has 17 pending or approved patent applications. Any challenges to these patents or delays in securing them could impact competitive advantage and market position.
Fiscal Year 2025 Revenue Guidance: The company expects product revenue to be in the range of $8 million to $10 million, representing an increase of between 132% and 190% over fiscal year 2024.
Product Gross Margin Expectations: The company has increased its product gross margin expectations to be between 50% and 53%, compared to the previous guidance of 47% to 51%. This is a significant improvement from 31% in fiscal year 2024.
Trigeminal Neuralgia Ablation Technology: If FDA clearance is obtained, the company expects to commercialize the product directly or with a strategic partner, with potential revenue generation from trigeminal nerve ablation starting late in calendar year 2025.
Lower Back Pain Treatment: The company is pursuing the use of its OneRF ablation system for basivertebral nerve ablation to treat lower back pain. This market represents a significant opportunity, with over $3 billion in annual revenue. First-in-man implants are expected in early 2026 if preclinical results are positive.
Spinal Cord Stimulation Electrode Technology: The company is advancing its spinal cord stimulation electrode technology, with first-in-man implants anticipated in early 2026 if chronic animal study results are positive. This market currently generates over $3 billion in annual revenue.
Drug Delivery System: The company received its first order from a leading biotech company to test its drug delivery system, which combines therapeutic and diagnostic capabilities. This system is still in development.
International Market Expansion: The company is working to secure ISO 13485 certification to commercialize and obtain regulatory clearances internationally. Success in this area could open significant revenue opportunities in the future.
The selected topic was not discussed during the call.
The earnings call reveals strong financial performance with significant improvements in gross margins and a reduced net loss. The strategic plan outlines ambitious growth prospects, including new product developments and market expansions. Although some uncertainty exists around partnerships and timelines, the overall sentiment is optimistic with increased revenue guidance and improved financial health. The Q&A section did not highlight any major concerns, supporting a positive outlook. Given these factors, a positive stock price movement is likely over the next two weeks.
The earnings call reveals strong financial performance, with significant revenue and margin growth, reduced expenses, and improved net loss. The partnership with Zimmer Biomet and international expansion plans are promising. Despite management's cautious stance on 2026 guidance, the optimistic FY 2025 outlook and strategic partnerships suggest a strong positive sentiment. The Q&A session highlights potential growth areas and addresses concerns, further solidifying the positive outlook. Given the context and potential for expansion, a strong positive stock price movement is expected, likely exceeding 8%.
The earnings call highlights strong financial performance, including record revenue and gross margins, a significant partnership with Zimmer Biomet, and improved net loss figures. The Q&A reveals reliance on Zimmer for revenue and some uncertainty regarding non-Zimmer revenue, but overall sentiment remains positive due to the partnership's potential and no debt. The capital raise ensures financial stability, and the addition of a Chief Medical Advisor indicates strategic growth. Despite some risks and uncertainties, the overall outlook is positive, likely resulting in a stock price increase of 2% to 8%.
NeuroOne's earnings report highlights strong financial performance with record product sales and gross margins, along with a significant partnership expansion with Zimmer Biomet. Despite some uncertainties in the Q&A, the company's improved financial health, no debt, and guidance of being fully funded through fiscal 2026 are positive indicators. The competitive pressures and supply chain challenges are present but are outweighed by the strategic partnership and financial improvements. The stock is likely to see a positive reaction over the next two weeks.
All transcripts are sourced directly from the official live webcast or the company’s official investor relations website. We use the exact words spoken during the call with no paraphrasing of the core discussion.
Full verbatim transcripts are typically published within 4–12 hours after the call ends. Same-day availability is guaranteed for all S&P 500 and most mid-cap companies.
No material content is ever changed or summarized in the “Full Transcript” section. We only correct obvious spoken typos (e.g., “um”, “ah”, repeated 10 times”, or clear misspoken ticker symbols) and add speaker names/titles for readability. Every substantive sentence remains 100% as spoken.
When audio quality is poor or multiple speakers talk over each other, we mark the section instead of guessing. This ensures complete accuracy rather than introducing potential errors.
They are generated by a specialized financial-language model trained exclusively on 15+ years of earnings transcripts. The model extracts financial figures, guidance, and tone with 97%+ accuracy and is regularly validated against human analysts. The full raw transcript always remains available for verification.
